Clinical Trial Update: A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-2206 in combination with AZD6244 in adults with locally advanced or metastatic solid tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumors

Drugs mentioned

• AZD6244 (selumetinib)
• MK-2206 (MK-2206)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Locally Advanced or Metastatic Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-08-07